Richard Greil
Impact in
Papers in
- Co-authors
- Michael Gnant (98 shared papers)Alexander Egle (96 shared papers)R. Jakesz (50 shared papers)Gabriel Rinnerthaler (58 shared papers)Simon Peter Gampenrieder (45 shared papers)Lisa Pleyer (38 shared papers)Inge Tinhofer (24 shared papers)Thomas Melchardt (76 shared papers)
- Journals
- Blood (99 papers)Journal of Clinical Oncology (99 papers)Annals of Oncology (46 papers)Cancer Research (24 papers)Clinical Cancer Research (16 papers)
- Partner nations
- AustriaGermanyUnited States
In The Last Decade
Richard Greil
704 papers receiving 20.1k citations
Richard Greil's Hit Papers
Peers
Comparison fields: 5 of 157
- Oncology 8.9k
- Genetics 2.8k
- Cancer Research 3.2k
- Pathology and Forensic Medicine 3.4k
- Hematology 2.2k
Countries citing papers authored by Richard Greil
This map shows the geographic impact of Richard Greil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Greil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Greil more than expected).
Fields of papers citing papers by Richard Greil
This network shows the impact of papers produced by Richard Greil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Greil. The network helps show where Richard Greil may publish in the future.
Co-authors
The 25 scholars most cited alongside Richard Greil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 736 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Hit paper breakdown → | 2012 | 843 |
| 2 | Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Hit paper breakdown → | 2005 | 645 |
| 3 | Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer Hit paper breakdown → | 2009 | 504 |
| 4 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Hit paper breakdown → | 2018 | 386 |
| 5 | 2011 | 337 | |
| 6 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial Hit paper breakdown → | 2020 | 329 |
| 7 | 2009 | 300 | |
| 8 | 2013 | 300 | |
| 9 | 2010 | 285 | |
| 10 | 2008 | 282 | |
| 11 | 2013 | 239 | |
| 12 | 2016 | 230 | |
| 13 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Hit paper breakdown → | 2022 | 216 |
| 14 | 2007 | 216 | |
| 15 | 2012 | 207 | |
| 16 | 2013 | 199 | |
| 17 | 2005 | 190 | |
| 18 | 2012 | 174 | |
| 19 | 2001 | 159 | |
| 20 | 1995 | 156 |
About Richard Greil
Richard Greil is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Molecular Biology, having authored 736 papers that have together received 20.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (138 papers), Chronic Lymphocytic Leukemia Research (136 papers), Cancer Treatment and Pharmacology (65 papers), Breast Cancer Treatment Studies (59 papers), Advanced Breast Cancer Therapies (59 papers), Colorectal Cancer Treatments and Studies (56 papers), Lung Cancer Treatments and Mutations (55 papers) and Multiple Myeloma Research and Treatments (55 papers). The work is most often cited by research in Oncology (8.9k citations), Genetics (2.8k citations), Cancer Research (3.2k citations), Pathology and Forensic Medicine (3.4k citations) and Hematology (2.2k citations). Richard Greil has collaborated with scholars based in Austria, Germany and United States. Frequent co-authors include Michael Gnant, Alexander Egle, R. Jakesz, Gabriel Rinnerthaler, Simon Peter Gampenrieder, Lisa Pleyer, Inge Tinhofer, Thomas Melchardt, Tanja Nicole Hartmann and Lukas Weiß. Their work appears in journals such as Blood, Journal of Clinical Oncology, Annals of Oncology, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.